WO1995032948A1 - Quinoline derivatives as tachykinin nk3 receptor antagonists - Google Patents
Quinoline derivatives as tachykinin nk3 receptor antagonists Download PDFInfo
- Publication number
- WO1995032948A1 WO1995032948A1 PCT/EP1995/002000 EP9502000W WO9532948A1 WO 1995032948 A1 WO1995032948 A1 WO 1995032948A1 EP 9502000 W EP9502000 W EP 9502000W WO 9532948 A1 WO9532948 A1 WO 9532948A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carboxamide
- phenylquinoline
- benzyl
- methoxycarbonyl
- ethylbenzyl
- Prior art date
Links
- 0 CC1(*)C=Cc2nc(*)c(*)c(C(N(*)C(*)(*)[Al])=*)c2C=C1 Chemical compound CC1(*)C=Cc2nc(*)c(*)c(C(N(*)C(*)(*)[Al])=*)c2C=C1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
- C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
Description
Claims
Priority Applications (27)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL95358624A PL188872B1 (en) | 1995-05-23 | 1995-05-23 | Quinoline derivatives as tachykinin nk3 receptor antagonists |
DE69531458T DE69531458T2 (en) | 1994-05-27 | 1995-05-23 | CHINOLINE DERIVATIVES AS TACHYKININ NK3 RECEPTOR ANTAGONISTS |
DK98204483T DK0940391T3 (en) | 1995-05-23 | 1995-05-23 | Quinoline derivatives as tachykinin NK3 receptor antagonists |
RO96-02234A RO114445B1 (en) | 1994-05-27 | 1995-05-23 | Quinoline derivatives, antagonists of nk3 tachiquinine receptor, process for preparation, pharmaceutical compositions containing the same and method of treatment |
KR1019960706701A KR100316571B1 (en) | 1994-05-27 | 1995-05-23 | Quinoline derivatives as tachykinin NK3 receptor antagonists |
CA002191352A CA2191352C (en) | 1994-05-27 | 1995-05-23 | Quinoline derivatives as tachykinin nk3 receptor antagonists |
CZ19963470A CZ291476B6 (en) | 1994-05-27 | 1995-05-23 | N-({alpha}-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide, pharmaceutical preparation containing it and use thereof |
NZ287442A NZ287442A (en) | 1994-05-27 | 1995-05-23 | 4-substituted quinoline derivatives; medicaments; use as an nk3 receptor antagonist |
SI9530687T SI0804419T1 (en) | 1994-05-27 | 1995-05-23 | Quinoline derivatives as tachykinin nk 3 receptor antagonists |
UA96124918A UA51623C2 (en) | 1994-05-27 | 1995-05-23 | Derivatives of quinoline as antagonists of nk3 receptor, method of their preparation, a pharmaceutical composition of their base and method of treatment |
JP50028796A JP3664492B2 (en) | 1994-05-27 | 1995-05-23 | Tachikinin NK ▲ Lower 3 ▼ Quinoline derivatives as receptor antagonists |
EP95920894A EP0804419B1 (en) | 1994-05-27 | 1995-05-23 | Quinoline derivatives as tachykinin nk 3 receptor antagonists |
SK1514-96A SK282721B6 (en) | 1994-05-27 | 1995-05-23 | Non-peptide NK3 antagonists, their production method, pharmaceuti cal preparations containing them and their use |
HU9603262A HU226535B1 (en) | 1994-05-27 | 1995-05-23 | Quinoline derivatives as tachykinin nk3 receptor antagonists, pharmaceutical compositions containing them, and their use |
SK47-99A SK282722B6 (en) | 1994-05-27 | 1995-05-23 | N-(alpha-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide, pharmaceutical preparation containing it and its use |
DK95920894T DK0804419T3 (en) | 1994-05-27 | 1995-05-23 | Quinoline derivatives as tachykinin NK 3 receptor antagonists |
AU26164/95A AU699319B2 (en) | 1994-05-27 | 1995-05-23 | Quinoline derivatives as tachykinin nk3 receptor antagonists |
AT95920894T ATE246677T1 (en) | 1994-05-27 | 1995-05-23 | QUINOLINE DERIVATIVES AS TACHYKININ NK3 RECEPTOR ANTAGONISTS |
BR9507788A BR9507788A (en) | 1994-05-27 | 1995-05-23 | Compound or solvate or salt of the same process for the preparation of the compound pharmaceutical composition NK3 receptor antagonist use of the compound use of the NG3 receptor antagonist and process for the treatment and / or prophylaxis of pulmonary disorders and seizure disorders |
PL95317381A PL186075B1 (en) | 1994-05-27 | 1995-05-23 | Derivatives of quinoline as antagonists of tachykynin receptors nk3 |
PL95341889A PL186665B1 (en) | 1994-05-27 | 1995-05-23 | Derivatives of quinoline as antagonists to receptors of the nk tachykinine. method of their manufacture, pharmaceutical composition containing quinoline derivatives and their application |
BG101008A BG64004B1 (en) | 1994-05-27 | 1996-11-25 | Quinoline derivatives as tachykinin nk3 receptor antagonists |
FI964712A FI115052B (en) | 1994-05-27 | 1996-11-26 | Quinoline derivatives as tachykinin NK3 receptor antagonists |
NO965036A NO307783B1 (en) | 1994-05-27 | 1996-11-26 | Quinoline derivatives such as tachykinin NK3 receptor antagonists, pharmaceutical preparations containing them and use of such derivatives |
FI990268A FI119721B (en) | 1994-05-27 | 1999-02-10 | Use of a non-peptide NK antagonist in the manufacture of a medicament for the treatment of skin diseases and itching |
BG103181A BG103181A (en) | 1994-05-27 | 1999-02-16 | The use of nonpeptide nk3 antagonists for the treatment of skin diseases and itching |
NO991813A NO326714B1 (en) | 1994-05-27 | 1999-04-16 | Use of quinoline derivatives for the preparation of pharmaceutical preparations for the treatment of skin diseases and itching. |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT94MI001099A ITMI941099A1 (en) | 1994-05-27 | 1994-05-27 | KINOLINIC DERIVATIVES |
ITMI94A001099 | 1994-05-27 | ||
ITMI950494 IT1293558B1 (en) | 1995-03-14 | 1995-03-14 | New tachykinin receptor antagonising quinoline derivs. - used for treating pulmonary disorders, CNS disorders, skin disorders, neurogenic inflammation, epilepsy and inflammatory pain,etc. |
ITMI95A000494 | 1995-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995032948A1 true WO1995032948A1 (en) | 1995-12-07 |
Family
ID=26331143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1995/002000 WO1995032948A1 (en) | 1994-05-27 | 1995-05-23 | Quinoline derivatives as tachykinin nk3 receptor antagonists |
Country Status (35)
Country | Link |
---|---|
US (5) | US6608083B1 (en) |
EP (2) | EP0804419B1 (en) |
JP (5) | JP3664492B2 (en) |
KR (1) | KR100316571B1 (en) |
CN (3) | CN1092642C (en) |
AP (1) | AP578A (en) |
AR (1) | AR037069A2 (en) |
AT (2) | ATE273959T1 (en) |
AU (1) | AU699319B2 (en) |
BG (2) | BG64004B1 (en) |
BR (1) | BR9507788A (en) |
CA (1) | CA2191352C (en) |
CZ (1) | CZ291476B6 (en) |
DE (2) | DE69533408T2 (en) |
DK (1) | DK0804419T3 (en) |
DZ (1) | DZ1889A1 (en) |
ES (2) | ES2227769T3 (en) |
FI (2) | FI115052B (en) |
HK (2) | HK1003884A1 (en) |
HU (1) | HU226535B1 (en) |
IL (1) | IL113844A (en) |
MA (1) | MA23560A1 (en) |
MX (1) | MX9605903A (en) |
MY (1) | MY129596A (en) |
NO (2) | NO307783B1 (en) |
NZ (1) | NZ287442A (en) |
OA (1) | OA10592A (en) |
PL (2) | PL186075B1 (en) |
PT (2) | PT940391E (en) |
RO (1) | RO114445B1 (en) |
SA (1) | SA95160290B1 (en) |
SK (2) | SK282721B6 (en) |
TW (2) | TW427977B (en) |
UA (1) | UA51623C2 (en) |
WO (1) | WO1995032948A1 (en) |
Cited By (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997019927A1 (en) * | 1995-11-24 | 1997-06-05 | Smithkline Beecham S.P.A. | Quinoline derivatives as nk3 antagonists |
WO1997019926A1 (en) * | 1995-11-24 | 1997-06-05 | Smithkline Beecham S.P.A. | Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 (nk-3)- and neurokinin 2 (nk-2) receptor antagonists. |
WO1997019928A1 (en) * | 1995-11-24 | 1997-06-05 | Smithkline Beecham S.P.A. | Salts of quinoline derivatives as nk3 antagonists |
WO1997021680A1 (en) * | 1995-11-24 | 1997-06-19 | Smithkline Beecham S.P.A. | Quinoline derivatives |
WO1998041506A1 (en) * | 1997-03-14 | 1998-09-24 | Smithkline Beecham Corporation | Novel quinoline- and naphthalenecarboxamides, pharmaceutical compositions and methods of inhibiting calpain |
WO1998052942A1 (en) * | 1997-05-23 | 1998-11-26 | Smithkline Beecham S.P.A. | Quinoline-4-carboxamide derivatives as nk-2 and nk-3 receptor antagonists |
WO2000031037A1 (en) * | 1998-11-20 | 2000-06-02 | Smithkline Beecham S.P.A. | Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists |
WO2000031038A1 (en) * | 1998-11-20 | 2000-06-02 | Smithkline Beecham S.P.A. | Quinoline derivatives as nk-2 and nk-3 receptor ligands |
EP1017676A1 (en) * | 1997-09-17 | 2000-07-12 | Smithkline Beecham Corporation | Method for the synthesis of quinoline derivatives |
EP1032393A1 (en) * | 1997-10-07 | 2000-09-06 | Cephalon, Inc. | QUINOLINE-CONTAINING $g(a)-KETOAMIDE CYSTEINE AND SERINE PROTEASE INHIBITORS |
US6369053B1 (en) | 1999-04-26 | 2002-04-09 | Neurogen Corporation | 2-Aminoquinolinecarboxamides: neurokinin receptor ligands |
US6413982B1 (en) | 1999-03-29 | 2002-07-02 | Neurogen Corporation | 4-substituted quinoline derivatives |
US6521618B2 (en) | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
WO2004002484A1 (en) * | 2002-06-26 | 2004-01-08 | Kyowa Hakko Kogyo Co., Ltd. | Phosphodiesterase inhibitor |
WO2004050627A1 (en) * | 2002-12-04 | 2004-06-17 | Smithkline Beecham Corporation | A quinoline amide derivative as agent against disorders of the cns |
WO2004050626A1 (en) * | 2002-12-04 | 2004-06-17 | Smithkline Beecham Corporation | A quinoline amide derivative as agent against disorders of the cns |
WO2005094801A1 (en) * | 2004-03-25 | 2005-10-13 | Smithkline Beecham Corporation | Use of an nk3 antagonist for the treatment of bipolar disorders |
EP1652840A2 (en) * | 1997-09-17 | 2006-05-03 | Smithkline Beecham Corporation | (-)-(S)-N-(.alpha.-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide |
WO2006050991A1 (en) * | 2004-11-12 | 2006-05-18 | Smithkline Beecham Corporation | Compounds having activity at nk3 receptor and uses thereof in medicine |
WO2006130080A2 (en) * | 2005-06-03 | 2006-12-07 | Astrazeneca Ab | Quinoline derivatives as nk3 anatgonists |
WO2006137789A1 (en) * | 2005-06-23 | 2006-12-28 | Astrazeneca Ab | Quinoline 3 -sulfonate esters as NK3 receptor modulators |
WO2007012900A1 (en) | 2005-07-29 | 2007-02-01 | Merck Sharp & Dohme Limited | Quinoline derivatives as neurokinin receptor antagonists |
WO2007018469A1 (en) * | 2005-08-11 | 2007-02-15 | Astrazeneca Ab | Oxopyridyl quinoline amides as nk3 receptor modulators |
WO2007018465A1 (en) * | 2005-08-11 | 2007-02-15 | Astrazeneca Ab | Amide alkyl pyridiyl quinolines as nk3 receptor modulators |
WO2007035157A1 (en) * | 2005-09-21 | 2007-03-29 | Astrazeneca Ab | Alkylnitrile quinolines, as nk-3 receptor ligands |
WO2007035158A1 (en) * | 2005-09-21 | 2007-03-29 | Astrazeneca Ab | Alkyl sulfoxide quinolines as nk-3 receptor ligands |
WO2007069977A1 (en) * | 2005-12-12 | 2007-06-21 | Astrazeneca Ab | Alkylsulphonamide quinolines |
WO2007093587A1 (en) * | 2006-02-15 | 2007-08-23 | Glaxo Group Limited | Use of r-(-)-2,4-diamino-5-(2, 3-dichlorophenyl)-6-fluoromethyl pyrimidine for the treatment of psychotic disorders |
US7368573B2 (en) | 2004-02-04 | 2008-05-06 | Pfizer Inc. | Triamide-substituted heterobicyclic compounds |
EP1919871A2 (en) * | 2005-08-02 | 2008-05-14 | Smithkline Beecham Corporation | Method for the synthesis of quinoli e derivatives |
WO2008131779A1 (en) * | 2007-04-26 | 2008-11-06 | H. Lundbeck A/S | Isoquinolinone derivatives as nk3 antagonists |
WO2009156339A1 (en) * | 2008-06-23 | 2009-12-30 | H. Lundbeck A/S | Isoquinolinone derivatives as nk3 antagonists |
WO2010045948A1 (en) | 2008-10-20 | 2010-04-29 | H. Lundbeck A/S | Isoquinolinone derivatives as nk3 antagonists |
WO2011072691A1 (en) | 2009-12-15 | 2011-06-23 | H. Lundbeck A/S | Pyridone derivatives as nk3 antagonists |
US7988964B2 (en) | 2003-12-22 | 2011-08-02 | Glaxo Group Limited | NOGO-a neutralising immunoglobulin for treatment of neurological diseases |
WO2011110183A1 (en) | 2010-03-12 | 2011-09-15 | H. Lundbeck A/S | Azaisoquinolinone derivatives as nk3 antagonists |
US8173639B2 (en) | 2007-04-26 | 2012-05-08 | H. Lundbeck A/S | Isoquinolinone derivatives as NK3 antagonists |
US8242134B2 (en) | 2008-09-15 | 2012-08-14 | H. Lundbeck A/S | Isoquinolinone derivatives as NK3 antagonists |
US8362208B2 (en) | 2005-12-16 | 2013-01-29 | Glaxo Group Limited | Immunoglobulins |
WO2013107820A1 (en) * | 2012-01-17 | 2013-07-25 | Universiteit Antwerpen | Novel fap inhibitors |
WO2016037954A1 (en) | 2014-09-09 | 2016-03-17 | Bayer Pharma Aktiengesellschaft | Substituted n,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents |
US9475773B2 (en) | 2013-04-19 | 2016-10-25 | Astrazeneca Ab | NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS) |
WO2017072629A1 (en) | 2015-10-29 | 2017-05-04 | Cadila Healthcare Limited | Pharmaceutical combination of nk3 receptor antagonist and biguanides |
US9670163B2 (en) | 2005-12-28 | 2017-06-06 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
US9701639B2 (en) | 2014-10-07 | 2017-07-11 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
US9751839B2 (en) | 2009-03-20 | 2017-09-05 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
WO2017153231A1 (en) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituted n-cyclo-2-aryl-isoquinolinone-4-carboxamides and use thereof |
WO2017153234A1 (en) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituted n-cyclo-2-aryl-quinoline-4-carboxamides and use thereof |
WO2017153235A1 (en) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituted n-cyclo-3-aryl-1-naphthamides and use thereof |
WO2018189012A1 (en) | 2017-04-10 | 2018-10-18 | Bayer Aktiengesellschaft | Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof |
WO2018189011A1 (en) | 2017-04-10 | 2018-10-18 | Bayer Aktiengesellschaft | Substituted n-arylethyl-2-arylquinoline-4-carboxamides and use thereof |
US10117864B2 (en) | 2015-03-18 | 2018-11-06 | Bayer Pharma Aktiengesellschaft | Substituted N-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof |
US10272046B2 (en) | 2012-02-27 | 2019-04-30 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
US10646481B2 (en) | 2008-08-13 | 2020-05-12 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
US10662192B2 (en) | 2004-06-24 | 2020-05-26 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
EP3915560A1 (en) | 2014-06-25 | 2021-12-01 | Emory University | Methods of managing conditioned fear with neurokinin receptor antagonists |
EP3881843A4 (en) * | 2018-11-15 | 2022-08-03 | Kyushu University, National University Corporation | Prophylactic or therapeutic agent and medicinal composition for il-31-mediated disease |
US11458129B2 (en) | 2017-11-02 | 2022-10-04 | California Institute Of Technology | Neurokinin antagonists and uses thereof |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ287442A (en) * | 1994-05-27 | 1998-05-27 | Smithkline Beecham Spa | 4-substituted quinoline derivatives; medicaments; use as an nk3 receptor antagonist |
AU757836B2 (en) * | 1995-11-24 | 2003-03-06 | Smithkline Beecham Spa | Quinoline derivatives |
US6077850A (en) * | 1997-04-21 | 2000-06-20 | G.D. Searle & Co. | Substituted benzopyran analogs for the treatment of inflammation |
US20010012846A1 (en) * | 1997-05-23 | 2001-08-09 | Glardina Giuseppe Arnaldo Maria | Quinoline-4-carboxamide derivatives as NK-2 and NK-3 receptor antagonists |
US6780875B2 (en) * | 1998-11-20 | 2004-08-24 | Smithkline Beecham S.P.A. | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists |
WO2000043008A1 (en) * | 1999-01-25 | 2000-07-27 | Smithkline Beecham Corporation | Anti-androgens and methods for treating disease |
US7037922B1 (en) * | 2000-03-10 | 2006-05-02 | Neurogen Corporation | Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands |
AU2001276556A1 (en) * | 2000-08-11 | 2002-02-25 | Smithkline Beecham P.L.C. | Novel pharmaceutical use of quinnoline derivatives |
GB0028964D0 (en) * | 2000-11-28 | 2001-01-10 | Smithkline Beecham Spa | Novel compounds |
US6540733B2 (en) * | 2000-12-29 | 2003-04-01 | Corazon Technologies, Inc. | Proton generating catheters and methods for their use in enhancing fluid flow through a vascular site occupied by a calcified vascular occlusion |
JP2004525184A (en) * | 2001-04-11 | 2004-08-19 | グラクソスミスクライン・ソシエタ・ペル・アチオニ | 3-Substituted quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists |
US20040152727A1 (en) * | 2001-05-18 | 2004-08-05 | Hay Douglas William Pierre | Novel use |
GB0312609D0 (en) | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
SE0302139D0 (en) * | 2003-07-28 | 2003-07-28 | Astrazeneca Ab | Novel compounds |
DE602005005033T2 (en) * | 2004-03-30 | 2009-03-19 | Smithkline Beecham Corp. | SPRAY-DRIED PHARMACEUTICAL COMPOSITIONS |
US8354427B2 (en) * | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
GB0417559D0 (en) * | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Therapeutic compounds |
GB0417560D0 (en) * | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Therapeutic compounds |
GB0425075D0 (en) * | 2004-11-12 | 2004-12-15 | Smithkline Beecham Corp | Novel compounds |
GB0425076D0 (en) * | 2004-11-12 | 2004-12-15 | Smithkline Beecham Corp | Novel compounds |
GB0428233D0 (en) * | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Compounds |
CN101268052A (en) * | 2005-09-21 | 2008-09-17 | 阿斯利康(瑞典)有限公司 | N-oxo-heterocycle and N-oxo-alkyl quinoline-4-carboxamides as NK-3 receptor ligands |
CN101374849A (en) * | 2005-12-24 | 2009-02-25 | 沃泰克斯药物股份有限公司 | Quinoline-4-ketones derivates as ABC transport protein regulation/control agent |
WO2007086799A1 (en) * | 2006-01-27 | 2007-08-02 | Astrazeneca Ab | Amide substituted quinolines |
AU2008228067B2 (en) | 2007-03-22 | 2011-12-08 | Astrazeneca Ab | Quinoline derivatives for the treatment of inflammatory diseases |
JP2010536872A (en) * | 2007-08-22 | 2010-12-02 | アラーガン、インコーポレイテッド | Therapeutic quinoline and naphthalene derivatives |
WO2009049791A2 (en) * | 2007-10-15 | 2009-04-23 | F. Hoffmann-La Roche Ag | Radiolabeled nk3 receptor antagonist |
PE20091036A1 (en) | 2007-11-30 | 2009-08-15 | Astrazeneca Ab | QUINOLINE DERIVATIVE AS ANTAGONIST OF THE P2X7 RECEPTOR |
US8487102B2 (en) * | 2010-04-20 | 2013-07-16 | Hoffmann-La Roche Inc. | Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists |
US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
CN102702099A (en) * | 2012-06-21 | 2012-10-03 | 江苏恩华药业股份有限公司 | Preparation method of (S)-3-hydroxy-2-phenyl-N-(1-phenylpropyl) quinoline-4-formamide |
WO2016004035A1 (en) * | 2014-07-01 | 2016-01-07 | Icahn School Of Medicine At Mount Sinai | 2-aryl-4-quinolinecarboxamide derivatives for treating thyroid diseases |
MX2017012720A (en) * | 2015-05-18 | 2018-02-09 | Nerre Therapeutics Ltd | Dual nk-1/nk-3 receptor antagonists for the treatment of sex-hormone-dependent diseases. |
CN105884626B (en) * | 2016-05-04 | 2017-10-20 | 龙曦宁(上海)医药科技有限公司 | A kind of synthetic method of 2 aminoidan derivatives and products thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1560489A (en) * | 1976-05-21 | 1980-02-06 | Fisons Ltd | Pharmaceutical compositions |
FR2538388B1 (en) | 1982-12-24 | 1985-06-21 | Pharmuka Lab | NOVEL NAPHTHALENE- OR AZANAPHTHALENECARBOXAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS |
DE3905339A1 (en) | 1989-02-22 | 1990-09-06 | Basf Ag | CHINOLINE-4-CARBONATEURED DERIVATIVES AND THEIR USE |
US5037835A (en) * | 1989-10-24 | 1991-08-06 | Hoechst-Roussel Pharmaceuticals Inc. | Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders |
US4992448A (en) * | 1989-10-24 | 1991-02-12 | Hoechst-Roussel Pharmaceuticals Inc. | Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders |
EP0449565B1 (en) * | 1990-03-26 | 1997-05-14 | Matsushita Electric Industrial Co., Ltd. | Photosensitive material for electrophotography |
US5482967A (en) * | 1992-09-04 | 1996-01-09 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic compounds, their production and use |
US5434158A (en) * | 1994-04-26 | 1995-07-18 | Merck & Co., Inc. | Spiro-substituted azacycles as neurokinin-3 antagonists |
NZ287442A (en) | 1994-05-27 | 1998-05-27 | Smithkline Beecham Spa | 4-substituted quinoline derivatives; medicaments; use as an nk3 receptor antagonist |
US5607936A (en) * | 1994-09-30 | 1997-03-04 | Merck & Co., Inc. | Substituted aryl piperazines as neurokinin antagonists |
-
1995
- 1995-05-23 NZ NZ287442A patent/NZ287442A/en not_active IP Right Cessation
- 1995-05-23 AU AU26164/95A patent/AU699319B2/en not_active Ceased
- 1995-05-23 RO RO96-02234A patent/RO114445B1/en unknown
- 1995-05-23 SK SK1514-96A patent/SK282721B6/en not_active IP Right Cessation
- 1995-05-23 PT PT98204483T patent/PT940391E/en unknown
- 1995-05-23 EP EP95920894A patent/EP0804419B1/en not_active Expired - Lifetime
- 1995-05-23 WO PCT/EP1995/002000 patent/WO1995032948A1/en active IP Right Grant
- 1995-05-23 EP EP98204483A patent/EP0940391B1/en not_active Expired - Lifetime
- 1995-05-23 HU HU9603262A patent/HU226535B1/en not_active IP Right Cessation
- 1995-05-23 DE DE69533408T patent/DE69533408T2/en not_active Expired - Lifetime
- 1995-05-23 DE DE69531458T patent/DE69531458T2/en not_active Expired - Lifetime
- 1995-05-23 ES ES98204483T patent/ES2227769T3/en not_active Expired - Lifetime
- 1995-05-23 PT PT95920894T patent/PT804419E/en unknown
- 1995-05-23 BR BR9507788A patent/BR9507788A/en not_active IP Right Cessation
- 1995-05-23 PL PL95317381A patent/PL186075B1/en not_active IP Right Cessation
- 1995-05-23 JP JP50028796A patent/JP3664492B2/en not_active Expired - Fee Related
- 1995-05-23 PL PL95341889A patent/PL186665B1/en not_active IP Right Cessation
- 1995-05-23 CA CA002191352A patent/CA2191352C/en not_active Expired - Fee Related
- 1995-05-23 CZ CZ19963470A patent/CZ291476B6/en not_active IP Right Cessation
- 1995-05-23 UA UA96124918A patent/UA51623C2/en unknown
- 1995-05-23 KR KR1019960706701A patent/KR100316571B1/en not_active IP Right Cessation
- 1995-05-23 AT AT98204483T patent/ATE273959T1/en not_active IP Right Cessation
- 1995-05-23 DK DK95920894T patent/DK0804419T3/en active
- 1995-05-23 CN CN95194338A patent/CN1092642C/en not_active Expired - Fee Related
- 1995-05-23 AT AT95920894T patent/ATE246677T1/en not_active IP Right Cessation
- 1995-05-23 SK SK47-99A patent/SK282722B6/en not_active IP Right Cessation
- 1995-05-23 ES ES95920894T patent/ES2204952T3/en not_active Expired - Lifetime
- 1995-05-24 AP APAP/P/1995/000745A patent/AP578A/en active
- 1995-05-24 DZ DZ950061A patent/DZ1889A1/en active
- 1995-05-25 US US08/450,437 patent/US6608083B1/en not_active Expired - Fee Related
- 1995-05-25 IL IL11384495A patent/IL113844A/en not_active IP Right Cessation
- 1995-05-25 MY MYPI95001381A patent/MY129596A/en unknown
- 1995-05-25 MA MA23898A patent/MA23560A1/en unknown
- 1995-05-25 US US08/450,438 patent/US5811553A/en not_active Expired - Lifetime
- 1995-05-26 TW TW084105319A patent/TW427977B/en not_active IP Right Cessation
- 1995-05-26 TW TW088121625A patent/TW533199B/en not_active IP Right Cessation
- 1995-10-03 SA SA95160290A patent/SA95160290B1/en unknown
-
1996
- 1996-11-25 BG BG101008A patent/BG64004B1/en unknown
- 1996-11-26 NO NO965036A patent/NO307783B1/en unknown
- 1996-11-26 MX MX9605903A patent/MX9605903A/en not_active IP Right Cessation
- 1996-11-26 FI FI964712A patent/FI115052B/en active IP Right Grant
- 1996-11-27 OA OA60928A patent/OA10592A/en unknown
-
1998
- 1998-04-09 HK HK98103021A patent/HK1003884A1/en not_active IP Right Cessation
-
1999
- 1999-01-15 CN CN99100978A patent/CN1276211A/en active Pending
- 1999-02-10 FI FI990268A patent/FI119721B/en active IP Right Grant
- 1999-02-16 BG BG103181A patent/BG103181A/en unknown
- 1999-04-16 NO NO991813A patent/NO326714B1/en unknown
- 1999-06-18 JP JP11172597A patent/JP2000026314A/en active Pending
-
2000
- 2000-03-06 HK HK00101401A patent/HK1024469A1/en not_active IP Right Cessation
- 2000-06-22 AR ARP000103117A patent/AR037069A2/en unknown
-
2001
- 2001-05-29 US US09/867,133 patent/US20030236281A1/en not_active Abandoned
- 2001-10-24 JP JP2001326622A patent/JP2002179594A/en active Pending
-
2002
- 2002-03-18 CN CN02107941A patent/CN1428145A/en active Pending
-
2004
- 2004-09-30 JP JP2004287629A patent/JP2005068155A/en active Pending
- 2004-11-29 US US10/999,180 patent/US20050096316A1/en not_active Abandoned
-
2006
- 2006-03-21 US US11/385,461 patent/US7482458B2/en not_active Expired - Fee Related
- 2006-12-28 JP JP2006355694A patent/JP2007126475A/en not_active Ceased
Non-Patent Citations (1)
Title |
---|
No relevant documents disclosed * |
Cited By (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6432977B1 (en) | 1995-11-24 | 2002-08-13 | Smithkline Beecham S.P.A. | Salts of quinoline derivatives as NK3 antagonists |
WO1997019926A1 (en) * | 1995-11-24 | 1997-06-05 | Smithkline Beecham S.P.A. | Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 (nk-3)- and neurokinin 2 (nk-2) receptor antagonists. |
WO1997019928A1 (en) * | 1995-11-24 | 1997-06-05 | Smithkline Beecham S.P.A. | Salts of quinoline derivatives as nk3 antagonists |
WO1997021680A1 (en) * | 1995-11-24 | 1997-06-19 | Smithkline Beecham S.P.A. | Quinoline derivatives |
US6355654B1 (en) | 1995-11-24 | 2002-03-12 | Smithkline Beecham S.P.A. | Salts of quinoline derivatives as NK3 antagonists |
US6743804B2 (en) | 1995-11-24 | 2004-06-01 | Smithkline Beecham S P.A. | Quinoline derivatives as NK3 antagonists |
WO1997019927A1 (en) * | 1995-11-24 | 1997-06-05 | Smithkline Beecham S.P.A. | Quinoline derivatives as nk3 antagonists |
US6100267A (en) * | 1997-03-14 | 2000-08-08 | Smithkline Beecham Corporation | Quinoline- and naphthalenecarboxamides, pharmaceutical compositions and methods of inhibiting calpain |
EP1491533A2 (en) * | 1997-03-14 | 2004-12-29 | Cephalon, Inc. | Quinoline-and naphthalenecarboxamides, pharmaceutical compositions thereof and their use as calpain inhibitors |
WO1998041506A1 (en) * | 1997-03-14 | 1998-09-24 | Smithkline Beecham Corporation | Novel quinoline- and naphthalenecarboxamides, pharmaceutical compositions and methods of inhibiting calpain |
EP1491533A3 (en) * | 1997-03-14 | 2005-01-19 | Cephalon, Inc. | Quinoline-and naphthalenecarboxamides, pharmaceutical compositions thereof and their use as calpain inhibitors |
WO1998052942A1 (en) * | 1997-05-23 | 1998-11-26 | Smithkline Beecham S.P.A. | Quinoline-4-carboxamide derivatives as nk-2 and nk-3 receptor antagonists |
US6335448B1 (en) * | 1997-09-17 | 2002-01-01 | Smithkline Beecham Corporation | Method for the synthesis of quinoline derivatives |
AU744538B2 (en) * | 1997-09-17 | 2002-02-28 | Smithkline Beecham Corporation | Method for the synthesis of quinoline derivatives |
EP1017676A1 (en) * | 1997-09-17 | 2000-07-12 | Smithkline Beecham Corporation | Method for the synthesis of quinoline derivatives |
EP1652840A2 (en) * | 1997-09-17 | 2006-05-03 | Smithkline Beecham Corporation | (-)-(S)-N-(.alpha.-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide |
EP1652840A3 (en) * | 1997-09-17 | 2006-05-17 | Smithkline Beecham Corporation | (-)-(S)-N-(.alpha.-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide |
EP1017676A4 (en) * | 1997-09-17 | 2002-12-04 | Smithkline Beecham Corp | Method for the synthesis of quinoline derivatives |
EP1032393A4 (en) * | 1997-10-07 | 2002-06-12 | Cephalon Inc | Quinoline-containing alpha-ketoamide cysteine and serine protease inhibitors |
EP1032393A1 (en) * | 1997-10-07 | 2000-09-06 | Cephalon, Inc. | QUINOLINE-CONTAINING $g(a)-KETOAMIDE CYSTEINE AND SERINE PROTEASE INHIBITORS |
US6613770B1 (en) | 1998-11-20 | 2003-09-02 | Smithkline Beecham S.P.A. | Quinoline derivatives as NK-2 and NK-3 receptor ligands |
AU768708B2 (en) * | 1998-11-20 | 2004-01-08 | Smithkline Beecham Laboratoires Pharmaceutiques | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists |
WO2000031038A1 (en) * | 1998-11-20 | 2000-06-02 | Smithkline Beecham S.P.A. | Quinoline derivatives as nk-2 and nk-3 receptor ligands |
WO2000031037A1 (en) * | 1998-11-20 | 2000-06-02 | Smithkline Beecham S.P.A. | Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists |
US6413982B1 (en) | 1999-03-29 | 2002-07-02 | Neurogen Corporation | 4-substituted quinoline derivatives |
US6624175B2 (en) | 1999-03-29 | 2003-09-23 | Neurogen Corporation | 4-Substituted quinoline derivatives |
US7041664B2 (en) | 1999-04-26 | 2006-05-09 | Neurogen Corporation | 2-aminoquinolinecarboxamides: neurokinin receptor ligands |
US6369053B1 (en) | 1999-04-26 | 2002-04-09 | Neurogen Corporation | 2-Aminoquinolinecarboxamides: neurokinin receptor ligands |
US6894044B2 (en) | 1999-04-26 | 2005-05-17 | Neurogen Corporation | 2-aminoquinolinecarboxamides: neurokinin receptor ligands |
US6689772B1 (en) | 2000-03-28 | 2004-02-10 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
US6521618B2 (en) | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
WO2004002484A1 (en) * | 2002-06-26 | 2004-01-08 | Kyowa Hakko Kogyo Co., Ltd. | Phosphodiesterase inhibitor |
WO2004050626A1 (en) * | 2002-12-04 | 2004-06-17 | Smithkline Beecham Corporation | A quinoline amide derivative as agent against disorders of the cns |
WO2004050627A1 (en) * | 2002-12-04 | 2004-06-17 | Smithkline Beecham Corporation | A quinoline amide derivative as agent against disorders of the cns |
US7988964B2 (en) | 2003-12-22 | 2011-08-02 | Glaxo Group Limited | NOGO-a neutralising immunoglobulin for treatment of neurological diseases |
US7368573B2 (en) | 2004-02-04 | 2008-05-06 | Pfizer Inc. | Triamide-substituted heterobicyclic compounds |
US7468378B2 (en) | 2004-02-04 | 2008-12-23 | Pfizer Inc. | Substituted quinoline compounds |
US7393958B2 (en) | 2004-02-04 | 2008-07-01 | Pfizer, Inc. | Triamide-substituted heterobicyclic compounds |
WO2005094801A1 (en) * | 2004-03-25 | 2005-10-13 | Smithkline Beecham Corporation | Use of an nk3 antagonist for the treatment of bipolar disorders |
US10662192B2 (en) | 2004-06-24 | 2020-05-26 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
WO2006050991A1 (en) * | 2004-11-12 | 2006-05-18 | Smithkline Beecham Corporation | Compounds having activity at nk3 receptor and uses thereof in medicine |
WO2006130080A2 (en) * | 2005-06-03 | 2006-12-07 | Astrazeneca Ab | Quinoline derivatives as nk3 anatgonists |
WO2006130080A3 (en) * | 2005-06-03 | 2007-01-25 | Astrazeneca Ab | Quinoline derivatives as nk3 anatgonists |
WO2006137789A1 (en) * | 2005-06-23 | 2006-12-28 | Astrazeneca Ab | Quinoline 3 -sulfonate esters as NK3 receptor modulators |
WO2007012900A1 (en) | 2005-07-29 | 2007-02-01 | Merck Sharp & Dohme Limited | Quinoline derivatives as neurokinin receptor antagonists |
EP1919871A2 (en) * | 2005-08-02 | 2008-05-14 | Smithkline Beecham Corporation | Method for the synthesis of quinoli e derivatives |
EP1919871A4 (en) * | 2005-08-02 | 2010-08-18 | Glaxosmithkline Llc | Method for the synthesis of quinoli e derivatives |
WO2007018469A1 (en) * | 2005-08-11 | 2007-02-15 | Astrazeneca Ab | Oxopyridyl quinoline amides as nk3 receptor modulators |
WO2007018465A1 (en) * | 2005-08-11 | 2007-02-15 | Astrazeneca Ab | Amide alkyl pyridiyl quinolines as nk3 receptor modulators |
US7964733B2 (en) | 2005-09-21 | 2011-06-21 | Astrazeneca Ab | Alkyl sulfoxide quinolines as NK-3 receptor ligands |
WO2007035157A1 (en) * | 2005-09-21 | 2007-03-29 | Astrazeneca Ab | Alkylnitrile quinolines, as nk-3 receptor ligands |
WO2007035158A1 (en) * | 2005-09-21 | 2007-03-29 | Astrazeneca Ab | Alkyl sulfoxide quinolines as nk-3 receptor ligands |
US8071621B2 (en) | 2005-12-12 | 2011-12-06 | Astrazeneca Ab | Alkylsulphonamide quinolines |
US7608628B2 (en) | 2005-12-12 | 2009-10-27 | Astrazeneca Ab | Alkylsulphonamide quinolines |
WO2007069977A1 (en) * | 2005-12-12 | 2007-06-21 | Astrazeneca Ab | Alkylsulphonamide quinolines |
AU2006325572B2 (en) * | 2005-12-12 | 2011-02-24 | Astrazeneca Ab | Alkylsulphonamide quinolines |
US8362208B2 (en) | 2005-12-16 | 2013-01-29 | Glaxo Group Limited | Immunoglobulins |
US10537565B2 (en) | 2005-12-28 | 2020-01-21 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
US11291662B2 (en) | 2005-12-28 | 2022-04-05 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
US9931334B2 (en) | 2005-12-28 | 2018-04-03 | Vertex Pharmaceuticals Incorporated | Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
US9670163B2 (en) | 2005-12-28 | 2017-06-06 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
WO2007093587A1 (en) * | 2006-02-15 | 2007-08-23 | Glaxo Group Limited | Use of r-(-)-2,4-diamino-5-(2, 3-dichlorophenyl)-6-fluoromethyl pyrimidine for the treatment of psychotic disorders |
WO2008131779A1 (en) * | 2007-04-26 | 2008-11-06 | H. Lundbeck A/S | Isoquinolinone derivatives as nk3 antagonists |
US8173639B2 (en) | 2007-04-26 | 2012-05-08 | H. Lundbeck A/S | Isoquinolinone derivatives as NK3 antagonists |
WO2009130240A1 (en) * | 2008-04-24 | 2009-10-29 | H. Lundbeck A/S | Isoquinolinone derivatives as nk3 antagonists |
US8420667B2 (en) | 2008-04-24 | 2013-04-16 | H. Lundbeck A/S | Isoquinolinone derivatives as NK3 antagonists |
WO2009156339A1 (en) * | 2008-06-23 | 2009-12-30 | H. Lundbeck A/S | Isoquinolinone derivatives as nk3 antagonists |
CN102123998A (en) * | 2008-06-23 | 2011-07-13 | H.隆德贝克有限公司 | Isoquinolinone derivatives as nk3 antagonists |
US8415356B2 (en) | 2008-06-23 | 2013-04-09 | H. Lundbeck A/S | Isoquinolinone derivatives as NK3 antagonists |
US11564916B2 (en) | 2008-08-13 | 2023-01-31 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
US10646481B2 (en) | 2008-08-13 | 2020-05-12 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
US8242134B2 (en) | 2008-09-15 | 2012-08-14 | H. Lundbeck A/S | Isoquinolinone derivatives as NK3 antagonists |
US8415373B2 (en) | 2008-10-20 | 2013-04-09 | H. Lundbeck A/S | Isoquinolinone derivatives as NK3 antagonists |
WO2010045948A1 (en) | 2008-10-20 | 2010-04-29 | H. Lundbeck A/S | Isoquinolinone derivatives as nk3 antagonists |
US9751839B2 (en) | 2009-03-20 | 2017-09-05 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
US8207347B2 (en) | 2009-12-15 | 2012-06-26 | H. Lundbeck A/S | Pyridone derivatives as NK3 antagonists |
WO2011072691A1 (en) | 2009-12-15 | 2011-06-23 | H. Lundbeck A/S | Pyridone derivatives as nk3 antagonists |
WO2011110183A1 (en) | 2010-03-12 | 2011-09-15 | H. Lundbeck A/S | Azaisoquinolinone derivatives as nk3 antagonists |
WO2013107820A1 (en) * | 2012-01-17 | 2013-07-25 | Universiteit Antwerpen | Novel fap inhibitors |
US9346814B2 (en) | 2012-01-17 | 2016-05-24 | Universiteit Antwerp | FAP inhibitors |
US11147770B2 (en) | 2012-02-27 | 2021-10-19 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
US10272046B2 (en) | 2012-02-27 | 2019-04-30 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
US11752106B2 (en) | 2012-02-27 | 2023-09-12 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
US9475773B2 (en) | 2013-04-19 | 2016-10-25 | Astrazeneca Ab | NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS) |
EP3915560A1 (en) | 2014-06-25 | 2021-12-01 | Emory University | Methods of managing conditioned fear with neurokinin receptor antagonists |
US10479765B2 (en) | 2014-09-09 | 2019-11-19 | Bayer Pharma Aktiengesellschaft | Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents |
WO2016037954A1 (en) | 2014-09-09 | 2016-03-17 | Bayer Pharma Aktiengesellschaft | Substituted n,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents |
US10189788B2 (en) | 2014-09-09 | 2019-01-29 | Bayer Pharma Aktiengesellschaft | Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents |
US9701639B2 (en) | 2014-10-07 | 2017-07-11 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
US10117864B2 (en) | 2015-03-18 | 2018-11-06 | Bayer Pharma Aktiengesellschaft | Substituted N-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof |
WO2017072629A1 (en) | 2015-10-29 | 2017-05-04 | Cadila Healthcare Limited | Pharmaceutical combination of nk3 receptor antagonist and biguanides |
WO2017153235A1 (en) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituted n-cyclo-3-aryl-1-naphthamides and use thereof |
WO2017153234A1 (en) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituted n-cyclo-2-aryl-quinoline-4-carboxamides and use thereof |
WO2017153231A1 (en) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituted n-cyclo-2-aryl-isoquinolinone-4-carboxamides and use thereof |
US11149018B2 (en) | 2017-04-10 | 2021-10-19 | Bayer Aktiengesellschaft | Substituted N-arylethyl-2-aminoquinoline-4-carboxamides and use thereof |
US11136296B2 (en) | 2017-04-10 | 2021-10-05 | Bayer Aktiengesellschaft | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof |
CN110730776A (en) * | 2017-04-10 | 2020-01-24 | 拜耳股份公司 | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and their use |
AU2018251758B2 (en) * | 2017-04-10 | 2021-11-18 | Bayer Aktiengesellschaft | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof |
AU2018251087B2 (en) * | 2017-04-10 | 2021-11-18 | Bayer Aktiengesellschaft | Substituted N-arylethyl-2-aminoquinoline-4-carboxamides and use thereof |
IL269843A (en) * | 2017-04-10 | 2019-11-28 | Bayer Pharma AG | Substituted n-arylethyl-2-arylquinoline-4-carboxamides and use thereof |
WO2018189011A1 (en) | 2017-04-10 | 2018-10-18 | Bayer Aktiengesellschaft | Substituted n-arylethyl-2-arylquinoline-4-carboxamides and use thereof |
TWI770157B (en) * | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof |
IL269836A (en) * | 2017-04-10 | 2019-11-28 | Bayer Pharma AG | Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof |
WO2018189012A1 (en) | 2017-04-10 | 2018-10-18 | Bayer Aktiengesellschaft | Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof |
US11458129B2 (en) | 2017-11-02 | 2022-10-04 | California Institute Of Technology | Neurokinin antagonists and uses thereof |
EP3881843A4 (en) * | 2018-11-15 | 2022-08-03 | Kyushu University, National University Corporation | Prophylactic or therapeutic agent and medicinal composition for il-31-mediated disease |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0940391B1 (en) | Quinoline derivatives as tachykinin NK3 receptor antagonists | |
US6743804B2 (en) | Quinoline derivatives as NK3 antagonists | |
US6355654B1 (en) | Salts of quinoline derivatives as NK3 antagonists | |
RU2155754C2 (en) | Quinoline derivatives as techychinin nk3 receptor antagonists | |
CA2257662C (en) | Quinoline derivatives as tachykinin nk3 receptor antagonists | |
PL188872B1 (en) | Quinoline derivatives as tachykinin nk3 receptor antagonists | |
AU5784501A (en) | Quinoline derivatives as tachykinin NK3 receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95194338.3 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 1996 737658 Country of ref document: US Date of ref document: 19961121 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 287442 Country of ref document: NZ Ref document number: 1199690394 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995920894 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2191352 Country of ref document: CA Ref document number: 151496 Country of ref document: SK Ref document number: 964712 Country of ref document: FI Ref document number: PV1996-3470 Country of ref document: CZ Ref document number: 1019960706701 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 96-02234 Country of ref document: RO |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV1996-3470 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1995920894 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4799 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 990268 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1999-552 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1996-3470 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995920894 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: PV1999-552 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 964712 Country of ref document: FI |